vs
Side-by-side financial comparison of Alpha Teknova, Inc. (TKNO) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
TRINITY BIOTECH PLC is the larger business by last-quarter revenue ($30.5M vs $10.0M, roughly 3.1× Alpha Teknova, Inc.). TRINITY BIOTECH PLC runs the higher net margin — -33.0% vs -47.7%, a 14.7% gap on every dollar of revenue. Alpha Teknova, Inc. produced more free cash flow last quarter ($-810.0K vs $-4.1M).
Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
TKNO vs TRIB — Head-to-Head
Income Statement — Q4 2025 vs Q2 2024
| Metric | | |
|---|---|---|
| Revenue | $10.0M | $30.5M |
| Net Profit | $-4.8M | $-10.1M |
| Gross Margin | 32.5% | 36.8% |
| Operating Margin | -46.2% | -23.2% |
| Net Margin | -47.7% | -33.0% |
| Revenue YoY | 7.8% | — |
| Net Profit YoY | 16.8% | — |
| EPS (diluted) | $-0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.0M | — | ||
| Q3 25 | $10.5M | — | ||
| Q2 25 | $10.3M | — | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | $9.3M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $9.6M | $30.5M | ||
| Q1 24 | $9.3M | — |
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-4.3M | — | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-4.6M | — | ||
| Q4 24 | $-5.7M | — | ||
| Q3 24 | $-7.6M | — | ||
| Q2 24 | $-5.4M | $-10.1M | ||
| Q1 24 | $-8.1M | — |
| Q4 25 | 32.5% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 38.7% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 29.2% | 36.8% | ||
| Q1 24 | 23.8% | — |
| Q4 25 | -46.2% | — | ||
| Q3 25 | -38.4% | — | ||
| Q2 25 | -32.9% | — | ||
| Q1 25 | -50.7% | — | ||
| Q4 24 | -60.7% | — | ||
| Q3 24 | -77.6% | — | ||
| Q2 24 | -53.0% | -23.2% | ||
| Q1 24 | -86.0% | — |
| Q4 25 | -47.7% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -34.7% | — | ||
| Q1 25 | -47.4% | — | ||
| Q4 24 | -61.7% | — | ||
| Q3 24 | -79.0% | — | ||
| Q2 24 | -55.8% | -33.0% | ||
| Q1 24 | -87.2% | — |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | $-0.09 | — | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.3M | $5.3M |
| Total DebtLower is stronger | $13.1M | — |
| Stockholders' EquityBook value | $68.8M | $-29.4M |
| Total Assets | $103.6M | $94.4M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.3M | — | ||
| Q3 25 | $22.1M | — | ||
| Q2 25 | $24.0M | — | ||
| Q1 25 | $26.3M | — | ||
| Q4 24 | $30.4M | — | ||
| Q3 24 | $31.7M | — | ||
| Q2 24 | $18.6M | $5.3M | ||
| Q1 24 | $21.6M | — |
| Q4 25 | $13.1M | — | ||
| Q3 25 | $13.1M | — | ||
| Q2 25 | $13.0M | — | ||
| Q1 25 | $13.0M | — | ||
| Q4 24 | $9.4M | — | ||
| Q3 24 | $10.9M | — | ||
| Q2 24 | $12.3M | — | ||
| Q1 24 | $13.2M | — |
| Q4 25 | $68.8M | — | ||
| Q3 25 | $72.7M | — | ||
| Q2 25 | $76.1M | — | ||
| Q1 25 | $78.6M | — | ||
| Q4 24 | $82.4M | — | ||
| Q3 24 | $87.3M | — | ||
| Q2 24 | $78.9M | $-29.4M | ||
| Q1 24 | $83.4M | — |
| Q4 25 | $103.6M | — | ||
| Q3 25 | $107.6M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $114.0M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $124.1M | — | ||
| Q2 24 | $115.4M | $94.4M | ||
| Q1 24 | $120.8M | — |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-462.0K | $-3.9M |
| Free Cash FlowOCF − Capex | $-810.0K | $-4.1M |
| FCF MarginFCF / Revenue | -8.1% | -13.3% |
| Capex IntensityCapex / Revenue | 3.5% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.8M | $-4.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-462.0K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | $-936.0K | — | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-2.8M | $-3.9M | ||
| Q1 24 | $-6.6M | — |
| Q4 25 | $-810.0K | — | ||
| Q3 25 | $-2.4M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-3.0M | $-4.1M | ||
| Q1 24 | $-6.7M | — |
| Q4 25 | -8.1% | — | ||
| Q3 25 | -22.6% | — | ||
| Q2 25 | -22.4% | — | ||
| Q1 25 | -44.0% | — | ||
| Q4 24 | -16.2% | — | ||
| Q3 24 | -25.0% | — | ||
| Q2 24 | -30.7% | -13.3% | ||
| Q1 24 | -71.8% | — |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 1.2% | 0.5% | ||
| Q1 24 | 1.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
TRIB
Segment breakdown not available.
